Shield Therapeutics (STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients’ unmet medical needs in renal and gastrointestinal disorders. Its initial focus is Feraccru® a supplement for iron deficiency. Following IPO and EU approval of Feraccru, both in February 2016, STX has made good progress with its de-risked commercial strategy. Management has secured agreements with three partners with expertise in rare diseases and European market access to accelerate Feraccru’s commercialisation. STX is now awaiting a game-changing FDA decision in 3Q’19 that could unlock the US market.
28 Jan 2019
Cast-iron investment
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Cast-iron investment
Shield Therapeutics Plc (STX:LON) | 2.0 0 0.0% | Mkt Cap: 15.6m
- Published:
28 Jan 2019 -
Author:
Martin Hall -
Pages:
8
Shield Therapeutics (STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients’ unmet medical needs in renal and gastrointestinal disorders. Its initial focus is Feraccru® a supplement for iron deficiency. Following IPO and EU approval of Feraccru, both in February 2016, STX has made good progress with its de-risked commercial strategy. Management has secured agreements with three partners with expertise in rare diseases and European market access to accelerate Feraccru’s commercialisation. STX is now awaiting a game-changing FDA decision in 3Q’19 that could unlock the US market.